SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI
SKBI was delisted on the 18th of December, 2015.
15 hedge funds and large institutions have $2.88M invested in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
36% more funds holding
Funds holding: 11 → 15 (+4)
4% more capital invested
Capital invested by funds: $2.77M → $2.88M (+$107K)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$109K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$21.6K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.49K |
| 4 |
Citigroup
New York
|
+$3.53K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$36K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$16.7K |
| 3 |
Renaissance Technologies
New York
|
-$11K |
| 4 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$3.88K |
| 5 |
SIM
Spark Investment Management
New York
|
-$1.29K |
SKBI Hedge Fund Activity: Q4 2014 in Review
15 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) for Q4 2014, worth a combined $2.88M — up 3.9% from $2.77M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SKBI positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Sabby Management, adding an estimated $109K. The largest seller was Morgan Stanley, exiting entirely with an estimated $36K sold.
- 15 institutional investors held SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) as of Q4 2014, up from 11 in Q3 2014.
- Funds reported $2.88M of SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) stock for Q4 2014, up 3.9% quarter-over-quarter.
- 5 funds opened new SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) positions in Q4 2014 and 1 closed out, a net change of +4 holders.
- The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) buyer in Q4 2014 was Sabby Management, an estimated $109K added.
- The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) seller in Q4 2014 was Morgan Stanley, an estimated $36K sold.
Based on aggregated 13F filings for Q4 2014.